US Stock MarketDetailed Quotes
SIOX Sio Gene Therapies
- 0.478000
- 0.0000000.00%
15min DelayClose Feb 7 16:00 ET
35.36MMarket Cap-1225P/E (TTM)
0.000000High0.000000Low0Volume0.000000Open0.478000Pre Close0.00Turnover0.00%Turnover RatioLossP/E (Static)73.98MShares0.50000052wk High0.78P/B22.98MFloat Cap0.25000052wk Low--Dividend TTM48.07MShs Float19.600000Historical High--Div YieldTTM0.00%Amplitude0.230300Historical Low--Avg Price1Lot Size
Sio Gene Therapies Key Stats
Quarterly+Annual
YOY
| (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | (FY)Mar 31, 2022 | (Q4)Mar 31, 2022 | (Q3)Dec 31, 2021 | (Q2)Sep 30, 2021 | (Q1)Jun 30, 2021 | (FY)Mar 31, 2021 | (Q4)Mar 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 76.11%-4.92M | 45.15%-5.08M | 31.39%-8.68M | -29.53%-60.35M | -74.03%-17.82M | -86.89%-20.61M | 21.60%-9.27M | 6.30%-12.65M | 30.95%-46.59M | 42.82%-10.24M |
| Net income from continuing operations | 84.21%-4.02M | 85.50%-3.08M | 29.18%-8.41M | -121.70%-71.89M | -300.00%-13.32M | -142.07%-25.46M | -112.71%-21.24M | -38.12%-11.87M | 55.35%-32.43M | 79.99%-3.33M |
| Operating gains losses | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -1,065.22%-11.26M | -3,485.77%-9.07M |
| Depreciation and amortization | --0 | -1,216.67%-134K | 146.36%271K | -72.99%666K | 65.74%479K | -89.78%65K | -98.07%12K | -88.03%110K | -20.30%2.47M | -59.64%289K |
| Other non cash items | 112.50%3K | 2,038.64%941K | -224.49%-159K | -4.59%-410K | -847.06%-381K | -164.86%-24K | 186.27%44K | 88.58%-49K | 74.92%-392K | 119.47%51K |
| Change In working capital | -133.21%-1.13M | -165.53%-3.03M | 89.46%-228K | 140.74%3.86M | -321.68%-2M | 265.79%3.41M | 232.99%4.62M | 55.37%-2.16M | -186.66%-9.47M | 122.49%904K |
| -Change in receivables | -200.00%-1K | --0 | 5,116.00%1.25M | -7.84%47K | 310.00%123K | -98.36%1K | -73.33%-52K | -150.00%-25K | 168.42%51K | -89.32%30K |
| -Change in prepaid assets | 267.50%1.55M | -75.14%486K | 123.23%2.39M | 148.75%2.13M | 102.79%30K | -6.58%-923K | 238.85%1.96M | 204.38%1.07M | -251.35%-4.38M | -264.53%-1.08M |
| -Change in payables and accrued expense | -161.79%-2.68M | -229.41%-3.51M | -20.68%-3.88M | 132.33%1.68M | -218.00%-2.16M | 433.38%4.33M | 242.04%2.71M | 15.77%-3.21M | 20.77%-5.19M | 136.90%1.83M |
| -Change in other current assets | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | -86.47%46K | 12,300.00%122K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 76.11%-4.92M | 45.15%-5.08M | 31.39%-8.68M | -29.53%-60.35M | -74.03%-17.82M | -86.89%-20.61M | 21.60%-9.27M | 6.30%-12.65M | 30.95%-46.59M | 42.82%-10.24M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | 1,364.29%177K | -106.65%-277K | -70.55%3.65M | -102.84%-359K | -21.37%-142K | 87.39%-14K | 22,010.53%4.16M | 4,957.25%12.39M | 252,760.00%12.63M |
| Net PPE purchase and sale | --0 | 1,364.29%177K | -53.89%-277K | -74.62%-695K | -137.75%-359K | -21.37%-142K | 87.39%-14K | -847.37%-180K | -56.08%-398K | -2,920.00%-151K |
| Net investment purchase and sale | --0 | --0 | --0 | -66.03%4.34M | --0 | --0 | --0 | --4.34M | --12.78M | --12.78M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --0 | 1,364.29%177K | -106.65%-277K | -70.55%3.65M | -102.84%-359K | -21.37%-142K | 87.39%-14K | 22,010.53%4.16M | 4,957.25%12.39M | 252,760.00%12.63M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 0 | 0 | 0 | -98.04%1.44M | 0 | -96.68%962K | 0 | 104.08%479K | 77.48%73.62M | -48.12%36.76M |
| Net issuance payments of debt | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | 46.79%-15.73M | --0 |
| Net common stock issuance | --0 | --0 | --0 | -98.39%1.44M | --0 | -96.68%962K | --0 | -87.81%479K | 26.01%89.23M | -48.15%36.72M |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -18.24%121K | -6.67%42K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | --0 | --0 | --0 | -98.04%1.44M | --0 | -96.68%962K | --0 | 104.08%479K | 77.48%73.62M | -48.12%36.76M |
| Net cash flow | ||||||||||
| Beginning cash position | -50.38%51.05M | -50.11%55.96M | -45.98%64.91M | 48.81%120.17M | 2.56%83.09M | 62.86%102.88M | 102.16%112.16M | 48.81%120.17M | -24.53%80.75M | 191.31%81.02M |
| Current changes in cash | 75.12%-4.92M | 47.14%-4.91M | -11.84%-8.96M | -240.18%-55.26M | -146.44%-18.18M | -210.85%-19.79M | -220.70%-9.28M | 68.30%-8.01M | 250.18%39.42M | -26.05%39.15M |
| End cash Position | -44.49%46.13M | -50.38%51.05M | -50.11%55.96M | -45.98%64.91M | -45.98%64.91M | 2.56%83.09M | 62.86%102.88M | 102.16%112.16M | 48.81%120.17M | 48.81%120.17M |
| Free cash flow | 76.28%-4.92M | 45.09%-5.1M | 30.19%-8.96M | -29.91%-61.04M | -74.95%-18.18M | -86.21%-20.75M | 22.21%-9.28M | 5.10%-12.83M | 30.62%-46.99M | 41.99%-10.39M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg